In addition, several inhibitors that specifically bind KRAS-G12C have been investigated in clinical trials, with sotorasib becoming the first treatment to gain approval for adults with stage IV NSCLC harboring a KRAS-G12C mutation as second-line therapy (26–30). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.